<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04375631</url>
  </required_header>
  <id_info>
    <org_study_id>RG1006914</org_study_id>
    <secondary_id>NCI-2020-02616</secondary_id>
    <secondary_id>RG1006914</secondary_id>
    <secondary_id>P30CA015704</secondary_id>
    <secondary_id>10457</secondary_id>
    <nct_id>NCT04375631</nct_id>
  </id_info>
  <brief_title>CLAG-M Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia</brief_title>
  <official_title>CLAGÂ·M Chemotherapy Followed Immediately by Related/Unrelated Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Cell Transplantation for Adults With Myeloid Malignancies at High Risk of Relapse: A Phase 1 Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the best dose of total body irradiation when given with CLAG-M
      chemotherapy reduced-intensity conditioning regimen before stem cell transplant in treating
      patients with acute myeloid leukemia, myelodysplastic syndrome, or chronic myelomonocytic
      leukemia that has come back (relapsed) or does not respond to treatment (refractory). Giving
      chemotherapy and total body irradiation before a donor peripheral blood stem cell transplant
      helps kill cancer cells in the body and helps make room in the patient's bone marrow for new
      blood-forming cells (stem cells) to grow. When the healthy stem cells from a donor are
      infused into a patient, they may help the patient's bone marrow make more healthy cells and
      platelets and may help destroy any remaining cancer cells. Sometimes the transplanted cells
      from a donor can attack the body's normal cells called graft versus host disease. Giving
      cyclophosphamide, cyclosporine, and mycophenolate mofetil after the transplant may stop this
      from happening.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE: This a dose-escalation study of TBI.

      Patients receive filgrastim (G-CSF) subcutaneously (SC) daily on days -9 to -4, cladribine
      intravenously (IV) over 2 hours daily on days -8 to -4, cytarabine IV over 2-4 hours daily on
      days -8 to -4, and mitoxantrone IV daily on days -8 to -6. If white blood cell (WBC) &gt;
      20,000/uL, filgrastim on days -9 and -8 may be omitted at physician discretion. Patients
      undergo TBI and HCT on day 0.

      GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 1-2 hours daily on days 3-4,
      cyclosporine IV over 1-2 hours twice daily (BID) on days 5-60, and mycophenolate mofetil IV
      or orally (PO) BID on days 5-28 (transplant with related donors) or three times daily (TID)
      on days 5-35 (transplant with unrelated donors). After day 60, patients continue to receive
      cyclosporine tapered through day 180 at the discretion of the treating physician in the
      absence of GVHD.

      After completion of study treatment, patients are followed up at 100 days, at 6, 12, and 24
      months post-transplant, then annually thereafter.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">December 26, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 26, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of hematopoietic cell transplantation (HCT) failure</measure>
    <time_frame>Within 200 days post-transplant</time_frame>
    <description>Defined as graft rejection (&lt; 5% donor T-cell chimerism).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of disease progression</measure>
    <time_frame>Within 200 days post-transplant</time_frame>
    <description>Defined by European LeukemiaNet (ELN) 2017 criteria and International Working Group (IWG).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 100 days post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of stem cell engraftment and donor chimerism</measure>
    <time_frame>At 80 days (+/- 7 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of grades II-IV acute graft versus host disease (GVHD) and chronic GVHD requiring systemic immunosuppressive treatment</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease response</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of remission</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Recurrent Acute Myeloid Leukemia</condition>
  <condition>Recurrent Chronic Myelomonocytic Leukemia</condition>
  <condition>Recurrent Myelodysplastic Syndrome</condition>
  <condition>Refractory Acute Myeloid Leukemia</condition>
  <condition>Refractory Chronic Myelomonocytic Leukemia</condition>
  <condition>Refractory Mixed Phenotype Acute Leukemia</condition>
  <condition>Refractory Myelodysplastic Syndrome</condition>
  <condition>Refractory Acute Leukemia of Ambiguous Lineage</condition>
  <condition>Refractory Acute Undifferentiated Leukemia</condition>
  <arm_group>
    <arm_group_label>Treatment (CLAG-M, TBI, HCT, GVHD prophylaxis)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive filgrastim SC daily on days -9 to -4, cladribine IV over 2 hours daily on days -8 to -4, cytarabine IV over 2-4 hours daily on days -8 to -4, and mitoxantrone IV daily on days -8 to -6. If WBC &gt; 20,000/uL, filgrastim on days -9 and -8 may be omitted at physician discretion. Patients undergo TBI and HCT on day 0.
GVHD PROPHYLAXIS: Patients receive cyclophosphamide IV over 1-2 hours daily on days 3-4, cyclosporine IV over 1-2 hours BID on days 5-60, and mycophenolate mofetil IV or PO BID on days 5-28 (transplant with related donors) or TID on days 5-35 (transplant with unrelated donors). After day 60, patients continue to receive cyclosporine tapered through day 180 at the discretion of the treating physician in the absence of GVHD.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cladribine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (CLAG-M, TBI, HCT, GVHD prophylaxis)</arm_group_label>
    <other_name>2-CdA</other_name>
    <other_name>2CDA</other_name>
    <other_name>CdA</other_name>
    <other_name>Cladribina</other_name>
    <other_name>Leustat</other_name>
    <other_name>Leustatin</other_name>
    <other_name>Leustatine</other_name>
    <other_name>RWJ-26251</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (CLAG-M, TBI, HCT, GVHD prophylaxis)</arm_group_label>
    <other_name>(-)-Cyclophosphamide</other_name>
    <other_name>2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate</other_name>
    <other_name>Carloxan</other_name>
    <other_name>Ciclofosfamida</other_name>
    <other_name>Ciclofosfamide</other_name>
    <other_name>Cicloxal</other_name>
    <other_name>Clafen</other_name>
    <other_name>Claphene</other_name>
    <other_name>CP monohydrate</other_name>
    <other_name>CTX</other_name>
    <other_name>CYCLO-cell</other_name>
    <other_name>Cycloblastin</other_name>
    <other_name>Cycloblastine</other_name>
    <other_name>Cyclophospham</other_name>
    <other_name>Cyclophosphamid monohydrate</other_name>
    <other_name>Cyclophosphamide Monohydrate</other_name>
    <other_name>Cyclophosphamidum</other_name>
    <other_name>Cyclophosphan</other_name>
    <other_name>Cyclophosphane</other_name>
    <other_name>Cyclophosphanum</other_name>
    <other_name>Cyclostin</other_name>
    <other_name>Cyclostine</other_name>
    <other_name>Cytophosphan</other_name>
    <other_name>Cytophosphane</other_name>
    <other_name>Cytoxan</other_name>
    <other_name>Fosfaseron</other_name>
    <other_name>Genoxal</other_name>
    <other_name>Genuxal</other_name>
    <other_name>Ledoxina</other_name>
    <other_name>Mitoxan</other_name>
    <other_name>Neosar</other_name>
    <other_name>Revimmune</other_name>
    <other_name>Syklofosfamid</other_name>
    <other_name>WR- 138719</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (CLAG-M, TBI, HCT, GVHD prophylaxis)</arm_group_label>
    <other_name>27-400</other_name>
    <other_name>Ciclosporin</other_name>
    <other_name>CsA</other_name>
    <other_name>Cyclosporin</other_name>
    <other_name>Cyclosporin A</other_name>
    <other_name>Cyclosporine Modified</other_name>
    <other_name>Gengraf</other_name>
    <other_name>Neoral</other_name>
    <other_name>OL 27-400</other_name>
    <other_name>Sandimmune</other_name>
    <other_name>SangCya</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (CLAG-M, TBI, HCT, GVHD prophylaxis)</arm_group_label>
    <other_name>.beta.-Cytosine arabinoside</other_name>
    <other_name>1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone</other_name>
    <other_name>1-Beta-D-arabinofuranosylcytosine</other_name>
    <other_name>1.beta.-D-Arabinofuranosylcytosine</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-</other_name>
    <other_name>2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-</other_name>
    <other_name>Alexan</other_name>
    <other_name>Ara-C</other_name>
    <other_name>ARA-cell</other_name>
    <other_name>Arabine</other_name>
    <other_name>Arabinofuranosylcytosine</other_name>
    <other_name>Arabinosylcytosine</other_name>
    <other_name>Aracytidine</other_name>
    <other_name>Aracytin</other_name>
    <other_name>Aracytine</other_name>
    <other_name>Beta-cytosine Arabinoside</other_name>
    <other_name>CHX-3311</other_name>
    <other_name>Cytarabinum</other_name>
    <other_name>Cytarbel</other_name>
    <other_name>Cytosar</other_name>
    <other_name>Cytosine Arabinoside</other_name>
    <other_name>Cytosine-.beta.-arabinoside</other_name>
    <other_name>Cytosine-beta-arabinoside</other_name>
    <other_name>Erpalfa</other_name>
    <other_name>Starasid</other_name>
    <other_name>Tarabine PFS</other_name>
    <other_name>U 19920</other_name>
    <other_name>U-19920</other_name>
    <other_name>Udicil</other_name>
    <other_name>WR-28453</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Filgrastim</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (CLAG-M, TBI, HCT, GVHD prophylaxis)</arm_group_label>
    <other_name>G-CSF</other_name>
    <other_name>Neupogen</other_name>
    <other_name>r-metHuG-CSF</other_name>
    <other_name>Recombinant Methionyl Human Granulocyte Colony Stimulating Factor</other_name>
    <other_name>rG-CSF</other_name>
    <other_name>Tevagrastim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hematopoietic Cell Transplantation</intervention_name>
    <description>Undergo HCT</description>
    <arm_group_label>Treatment (CLAG-M, TBI, HCT, GVHD prophylaxis)</arm_group_label>
    <other_name>HCT</other_name>
    <other_name>Hematopoietic Stem Cell Transplantation</other_name>
    <other_name>HSCT</other_name>
    <other_name>Stem Cell Transplant</other_name>
    <other_name>stem cell transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mitoxantrone</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (CLAG-M, TBI, HCT, GVHD prophylaxis)</arm_group_label>
    <other_name>Dihydroxyanthracenedione</other_name>
    <other_name>Mitozantrone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Mofetil</intervention_name>
    <description>Given IV or PO</description>
    <arm_group_label>Treatment (CLAG-M, TBI, HCT, GVHD prophylaxis)</arm_group_label>
    <other_name>Cellcept</other_name>
    <other_name>MMF</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate Sodium</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (CLAG-M, TBI, HCT, GVHD prophylaxis)</arm_group_label>
    <other_name>ERL 080</other_name>
    <other_name>ERL 080A</other_name>
    <other_name>Socium Mycophenolate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total-Body Irradiation</intervention_name>
    <description>Undergo TBI</description>
    <arm_group_label>Treatment (CLAG-M, TBI, HCT, GVHD prophylaxis)</arm_group_label>
    <other_name>TBI</other_name>
    <other_name>Total Body Irradiation</other_name>
    <other_name>Whole Body Irradiation</other_name>
    <other_name>Whole-Body Irradiation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hematopoietic Cell Transplantation-Comorbidity Index (HCT-CI) =&lt; 5 for patients over
             60 years

          -  Acute myeloid leukemia (AML) (2016 World Health Organization [WHO] criteria) that is
             either primary refractory (as defined by failure of 2 cycles of 7+3-like chemotherapy,
             1 cycle of high-dose cytarabine-based chemotherapy), or at least 2 cycles of
             venetoclax in combination with either low-dose cytarabine or an azanucleoside, or is
             in early (remission duration =&lt; 6 months) untreated relapse. Patients in morphological
             remission (i.e. &lt; 5% blasts in the bone marrow) but evidence of minimal residual
             disease (MRD) by multiparameter flow cytometry, cytogenetics/fluorescence in situ
             hybridization (FISH), or molecular means will be eligible for trial participation.
             Patients with refractory acute leukemia of ambiguous lineage (acute undifferentiated
             leukemia, mixed phenotype acute leukemia) are eligible

          -  Subjects with previously treated myelodysplastic syndrome (MDS) and chronic
             myelomonocytic leukemia (CMML), defined as prior treatment with at least one
             hypomethylating agent (HMA; azacitidine and/or decitabine) whose disease progressed,
             relapsed, or was refractory to HMA treatment as follows: patients who have failed at
             least 6 cycles of azacitidine or 4 cycles of decitabine

          -  The use of hydroxyurea prior to initiation of study treatment is allowed. Patients
             with symptoms/signs of hyperleukocytosis, WBC &gt; 100,000/uL or with concern for other
             complications of high tumor burden (e.g. disseminated intravascular coagulation) can
             be treated with leukapheresis or may receive up to 2 doses of cytarabine (up to 500
             mg/m^2 per dose) prior to start of study treatment

          -  Karnofsky score &gt;= 70; Eastern Cooperative Oncology Group (ECOG) 0-1

          -  Adequate cardiac function defined as absence of decompensated congestive heart failure
             and/or uncontrolled arrhythmia and left ventricular ejection fraction &gt;= 45%

          -  Bilirubin =&lt; 2.5 x institutional upper limit of normal unless elevation is thought to
             be due to hepatic infiltration by AML, Gilbert's syndrome, or hemolysis

          -  Adequate pulmonary function defined as absence of oxygen (O2) requirements and either
             carbon monoxide diffusing capability test (DLCO) correct &gt;= 70% mmHg or DLCO corrected
             60-69% mmHg and partial pressure of oxygen (pO2) &gt;= 70 mmHg

          -  Serum creatinine =&lt; 1.5 mg/dL

          -  Prior autologous HCT is permissible if relapse occurred &gt; 3 months but =&lt; 6 months
             after HCT

          -  Prior TBI-containing allogeneic HCT up to 3 Gy is permissible if &gt; 6 months after HCT

          -  A human leukocyte antigen (HLA)-matched or near-matched related or unrelated donor for
             collection of stimulated peripheral blood stem cells must be identified and readily
             available

          -  Women of childbearing potential and men must agree to use adequate contraception
             beginning at the signing of the consent until at least 12 months post-transplant

          -  Ability to understand and sign a written informed consent document (or legal
             representative)

          -  DONOR: Patients must have an HLA-matched related donor or an HLA-matched unrelated
             donor who meets standard SCCA and/or National Marrow Donor Program (NMDP) or other
             donor center criteria for peripheral blood stem cell (PBSC) donation as follows:

               -  Related donor: related to the patient and genotypically or phenotypically
                  identical for HLA-A, B, C, DRB1 and DQB1. Phenotypic identity must be confirmed
                  by high-resolution typing

               -  Unrelated donor:

                    -  Matched for HLA-A, B, C, DRB1 and DQB1 by high resolution typing; OR

                    -  Mismatched for a single allele without antigen mismatching at HLA-A, B, or C
                       as defined by high resolution typing but otherwise matched for HLA-A, B, C,
                       DRB1 and DQB1 by high resolution typing

                    -  Donors are excluded when preexisting immunoreactivity is identified that
                       would jeopardize donor hematopoietic cell engraftment. The recommended
                       procedure for patients with 10 of 10 HLA allele level (phenotypic) match is
                       to obtain panel reactive antibody (PRA) screens to class I and class II
                       antigens for all patients before HCT. If the PRA shows &gt; 10% activity, then
                       flow cytometric or B and T cell cytotoxic cross matches should be obtained.
                       The donor should be excluded if any of the cytotoxic cross match assays are
                       positive. For those patients with an HLA class I allele mismatch, flow
                       cytometric or B and T cell cytotoxic cross matches should be obtained
                       regardless of the PRA results. A positive anti-donor cytotoxic crossmatch is
                       an absolute donor exclusion

                    -  Patient and donor pairs homozygous at a mismatched allele in the graft
                       rejection vector are considered a two-allele mismatch, i.e., the patient is
                       A*0101 and the donor is A*0102, and this type of mismatch is not allowed

        Exclusion Criteria:

          -  Patients &gt;= 18 years being treated at Seattle Children's Hospital

          -  Active central nervous system (CNS) disease

          -  Prior treatment with cladribine, cytarabine and filgrastim (CLAG) or CLAG-M
             chemotherapy

          -  Concomitant illness associated with a likely survival of &lt; 1 year

          -  Active systemic fungal, bacterial, viral, or other infection, unless disease is under
             treatment with anti-microbials and/or controlled or stable. Patients with fever
             thought to be likely secondary to myeloid malignancy are eligible

          -  Known hypersensitivity or contraindication to any study drug used in this trial

          -  Pregnancy or lactation

          -  Concurrent treatment with any other approved or investigational anti-leukemia agent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Filippo Milano</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Filippo Milano</last_name>
    <phone>206.667.5925</phone>
    <email>fmilano@fredhutch.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Filippo Milano</last_name>
      <phone>206-667-5925</phone>
      <email>fmilano@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>Filippo Milano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>May 1, 2020</study_first_submitted>
  <study_first_submitted_qc>May 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 5, 2020</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Acute</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Chronic</mesh_term>
    <mesh_term>Leukemia, Myelomonocytic, Juvenile</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Mitoxantrone</mesh_term>
    <mesh_term>Cladribine</mesh_term>
    <mesh_term>2-chloro-3'-deoxyadenosine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Lenograstim</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

